Introduction
Acute myeloid leukemia (AML) is most often encountered in patients older than 65 years [1] . In this patient population, AML is associated with distinct biological and clinical features, which correlate with poor outcome. Older patients have a higher incidence of poorrisk cytogenetics than their younger counterparts [2] . They are more likely to develop AML in the setting of a pre-existing hematologic malignancy. Moreover, age has always been identified as a strong independent prognostic factor [3] .
At present, there is no treatment of choice for older patients with AML. Optimal treatment remains controversial due to important outcome disparities in this patient population among population-based data and clinical trials. Standard induction chemotherapy in older patients with AML remains a combination of intermediate-dose cytarabine with an anthracycline administered for 7 and 3 days ('7 + 3'), respectively [4] . With standard induction chemotherapy, 40 to 60% of older adults with newly diagnosed AML achieve a complete remission (CR).
However, median overall survival (OS) for this group of patients ranges from 7 to 12 months with only 10 and 2% of patients alive at 2 and 5 years, respectively [5] [6] [7] [8] . Optimal duration or intensity of consolidation therapy in older patients remains unclear. Up to 20% of older adults who achieved CR, enrolled in intensive chemotherapy trials, do not receive any consolidation therapy. Several studies have indicated that subsequent cycles of intensive chemotherapy following achievement of CR offered no benefit to patients [8, 9] . Despite encouraging early results, nonmyeloablative allogeneic hematopoietic cell transplantation remains only limited to a selected group of older patients [10] . Because of the poor outcome of elderly patients intensively treated with high mortality and morbidity rates and a significant decrease in quality of life, only a minority of elderly patients are suitable for standard intensive chemotherapy. Consequently, the development of low-intensity treatments based on novel agents has rapidly increased mainly for patients aged over 70 years.
Treatment is better than no treatment
Twenty years ago, the administration of supportive care was the only therapeutic option for about 60% of elderly AML patients. A retrospective analysis of cancer registry data between 1965 and 2003 found that fewer patients aged ≥60 years received chemotherapy compared with adult patients aged G60 years (29 versus 59%) [11] . Despite poor outcomes (median survival of 2 months for patients aged ≥65 years in a retrospective analysis of registry data between 1991 and 1996 [12] ), data from both population registries and clinical trials have demonstrated improved survival for older patients receiving intensive induction chemotherapy compared to those receiving supportive care alone [4, 13•] . The Swedish Acute Leukemia Registry including 998 patients aged 70 to 79 years of age has shown a survival advantage for intensive versus palliative therapy in this age group regardless of performance status [13•] . A landmark randomized trial comparing intensive induction to supportive care alone demonstrated a small but measurable improvement in survival for patients aged 65 years and over [4] . However, survival has improved over time in both registry data and clinical trials. This was related to a decline in treatment-related mortality rates over time, possibly as a result of improvements in best supportive care [14, 15] . The impact of intensive therapy on quality of life and functional status among older adults did not appear to differ significantly in survivors over 6 months [16] . However, for many older patients, the risk of treatment-related mortality may overweight the potential transient benefits of intensive therapy, especially in those aged ≥75 years and those with significant comorbidities or poor performance status [15] .
How to predict who will respond to intensive chemotherapy Although chronological age alone is not a good surrogate marker for predicting tolerability to intensive chemotherapy, older patients tend to have comorbidities that contribute to higher-rates of treatment-related mortality. Several prognostic models have been proposed to risk-stratify and predict outcome in patients undergoing standard induction chemotherapy [5, 17, 18] . Significant predictors of outcome were age ≥75 years, unfavorable cytogenetics, Eastern Cooperative Oncology Group (ECOG) performance status index 92, prior history of hematologic disorder, lactate dehydrogenase 9600 IU/L, elevated creatininemia, and treatment outside a laminar air flow room [5] . Other independent predictors of survival included CD34 expression, initial white blood cell count, and nucleophosmin 1 (NPM1) status [17] . The hematopoietic cell transplantation comorbidity index assessed in patients over 60 years of age receiving induction chemotherapy was shown predictive of early death rates and OS [19] . Although the prognostic impact of the FMS-like tyrosine kinase 3 (FLT3) and NPM1 mutations has been extensively studied in younger AML patients, few are known in older patients whether treated intensively or nonintensively, or in the context of prognostic scores. In a recent large study, it was shown that FLT3 mutation did not affect remission rate in intensively or nonintensively treated patients but was associated with an inferior survival [20] . Patients with a NPM1 mutation had a significantly higher remission rate, but survival was not improved. Detection of persisting leukemia-associated driver mutations during CR is common in older AML patients [21] . This likely indicates persistence of a preleukemic clone and might contribute to the inferior outcome of elderly AML patients. Chronological age by itself is not always reliable in estimating life expectancy, and the risk of treatment complications. Recently, comprehensive geriatric assessments have been developed. They include tools to predict the functional age based on functional status, comorbidities, polypharmacy, nutritional status, and geriatric syndromes [22] . These tools may replace chronologic age as an identifier of AML patients ineligible for aggressive treatment approaches. The G8 questionnaire represents a simple screening test to rapidly identify oncological patients requiring a full geriatric assessment [23] . Evolving set of criteria for fitness, vulnerability, and frailty based on performance status, comorbidity assessment, and cognitive assessment has been proposed [24••] . When combined with European LeukemiaNet (ELN) risk criteria [25•] , this model showed a high concordance (79%) between "fitness criteria" proposed and treatment actually received by patients [26] . Metrics for non-disease variables are therefore needed to help define the best treatment for each older patient. Patients with impairments in activities of daily living, Karnovsky index below 80%, quality of life/fatigue index of 50 or over are likely to have poor outcomes [27] . Cellular "senescence" refers to the specific phenomenon wherein a proportion of competent cells undergo permanent growth arrest in response to various cellular stresses. The decrease in immune function associated with aging leads to an increased sensitivity to infections, autoimmune disorders, and cancer development. The aging phenotype is partly explained by damages in DNA integrity resulting in poor DNA repair, telomere shortening, chromosomal instability, altered intercellular communication and senescent environment, and loss of apoptosis-regulating genes [28] . Biological cellular and molecular markers of frailty are still currently under investigation [29] . The expression of p16 in circulating T lymphocytes, a known biomarker of senescence, not only correlates with age but also with chemotherapy-related aging [30] .
Increasing role of hypomethylating agents
Among low-intensity therapies, hypomethylating agents (azacitidine and decitabine) have received substantial attention for the treatment of elderly AML patients who are unwilling or medically unfit to receive intensive chemotherapy. Hypomethylating agents are currently serving as comparator (instead of low-dose cytarabine) for studies testing new molecules in older patients unfit for intensive chemotherapy. Hypomethylating agents belong to nucleoside analogs that restore expression of tumor suppressor genes silenced by hypermethylation of DNA by inhibiting DNA methytransferase, an enzyme that catalyzes the addition of a methyl group to cytosine in CpG residues in DNA. Both have been approved in Europe for the treatment of adult AML. Combining DNMT inhibitors with histone deacetylase (HDAC) inhibitors has shown promising initial results [31] .
Azacitidine studies
Azacitidine has shown clinical activity in older patients with AML. In a phase 3 study, patients with high-risk myelodysplastic syndrome or AML were randomized to either azacitidine or best supportive care, with crossover to azacitidine permitted at the time of disease progression [32] . The azacitidine arm demonstrated significantly improved response rates and better quality of life measures. The AZA-001 trial compared the efficacy and safety of azacitidine with conventional care regimens (best supportive care, low-dose cytarabine, intensive chemotherapy) in patients with predominantly intermediate-2/high-risk myelodysplastic syndromes [33] . However, one third of these patients were with AML, when considering the World Health Organization (WHO) classification (20-30% blasts). In these patients, a significant difference in overall survival favoring azacitidine versus conventional care regimens was detected (median OS 24.5 versus 16.0 months). Furthermore, more patients with transfusion dependency at baseline achieved transfusion independence with azacitidine. Based on this analysis, azacitidine has become established as a treatment option for patients with 20 to 30% leukemia cells in bone marrow, who are ineligible for intensive chemotherapy. In the AZA-AML-001 trial, older AML patients with more than 30% leukemia cells in bone marrow were randomized to receive either azacitidine (75 mg/m 2 /day for 7 days every 4 weeks) or conventional care regimens [34•] . Median OS was better in the azacitidine arm (10.4 versus 6.5 months). The difference became significant when censoring patients at the start of the subsequent AML therapy (median OS 12.1 versus 6.9 months). No difference in 30-and 60-day mortality was found among the two treatment groups. A phase 2 evaluation of azacitidine plus lenalidomide in patients aged ≥65 years is currently recruiting patients (NCT01358734). Phase 1/2 data for this combination has shown an overall response rate of 41% and median OS of 20 weeks [35] . First results of combination of azacitidine with nivolumab, an anti-PD1, demonstrated efficacy in patients with relapsed AML [36] .
Decitabine studies
Decitabine was found to be clinically effective in the treatment of patients with high-risk myelodysplastic syndrome, by providing durable responses and improved time to AML transformation or death [37] . The DACO-016 study has compared the efficacy and safety of decitabine (20 mg/m 2 /day for 5 days every 4 weeks) versus best supportive care or low-dose cytarabine in older patients ineligible for intensive chemotherapy [38•] . The decitabine cohort demonstrated higher CR rates (17.8 versus 7.8%). While the first analysis demonstrated a non-significant trend towards improved overall survival in the decitabine arm, an unplanned ad hoc analysis performed 1 year later showed a significant difference between the two arms of randomization (median OS 7.7 versus 5 months) [38•] . The major toxicity was myelosuppression. A phase 2 singleinstitution study suggested that a higher CR rate can be achieved with decitabine given for 10 consecutive days [39] . The median time to response was three cycles and the 1-year survival was 30%. A phase 2 trial evaluating decitabine plus tosedostat (an orally bioavailable aminopeptidase inhibitor) versus tosedostat plus cytarabine (NCT01567059) was suspended due to a partial clinical hold being placed on tosedostat. A phase 2 evaluation of decitabine in combination with the proteasome inhibitor bortezomib is ongoing (NCT01420926). Phase 1 data for this combination demonstrated a response in 50% of cases [40] . The recent decitabine and thioguanine combination was well tolerated and showed surprising anti-leukemic activity [41] .
Cytogenetic and molecular prognostic factors with hypomethylating agents
Certain subtypes of patients may be more likely to respond to hypomethylating agents. Patients with morphologic dysplastic changes treated with azacitidine had twice the median survival than their similar counterparts treated with conventional therapy [42] . Hypomethylating agents may be more effective in AML patients with DNMT3A mutations [43] or with TET2 mutations [44, 45] . A recent study showed a survival improvement in patients with Evi-1 mutations treated by azacitidine [46] .
New therapies Second-generation hypomethylating agents
A possible alternative to decitabine is the novel DNA hypomethylating agent, SGI-110 (guadecitabine). It has the potential advantages of subcutaneous administration, better DNA hypomethylating effects at lower doses, and less myelosuppressive effects [47] . SGI-110 delivers decitabine with a fourfold longer half-life and overall exposure of up to 8 h. Potent dose-related DNA demethylation occurred on the daily ×5 regimen, reaching a plateau at 60 mg/ m 2 designated as the biologically effective dose. Response rate was 53% in a phase 2 first-line therapy in older patients with AML [48•] . Recently, a 10-day subcutaneous regimen using 60 mg/m 2 /day of SGI-110 on days 1-5 and 8-12 every 28 days for at least 2 to 4 cycles, followed by 60 mg/m 2 /day on days 1-5 every 28 days for a total of at least 6 cycles has also been reported [49] . The overall CR rate was 30% and the median OS was 7.2 months. A phase 3 randomized study comparing SGI-110 with treatment choice (low-dose cytarabine, decitabine, or azacitidine) is currently ongoing in older adults with previously untreated AML who are not considered candidates for intensive chemotherapy.
New nucleoside analogs
Clofarabine is a purine nucleoside analog, which acts to impair the synthesis and repair of DNA, and activates apoptotic pathways through disruption of mitochondrial membranes [50] . In older AML patients, the overall response rate was 38% and was significantly higher than that observed with low-dose cytarabine [51•] . However, this did not translate into an improvement in OS.
Clofarabine was more myelosuppressive than low-dose cytarabine leading to greater supportive care requirements, hospitalization durations, and days on antibiotics. In combination with low-dose cytarabine, clofarabine gave significant better results than clofarabine alone in terms of response rate (67 versus 31%), but not in terms of OS [52] .
Sapacitabine is an orally available nucleoside analog that interferes with DNA synthesis by introducing single-strand DNA breaks [53] . In a phase 2 study testing different schedules of sapacitabine, the drug was well tolerated. The 30-and 60-day mortality rates were 13 and 26%, respectively [54•] . Several clinical trials investigating sapacitabine as treatment for AML are currently ongoing, including a phase 3 trial comparing sapacitabine and decitabine, administered in alternating cycles, to decitabine alone, as first-line treatment for elderly patients with newly diagnosed AML (NCT01303796). This treatment combination has an acceptable safety profile. In a previous study, a response rate of 37% was observed and the 60-day mortality rate was 13% [55] .
A low-intensity program of cladribine followed by low-dose cytarabine alternating with decitabine has recently shown durable responses and a welltolerated ambulatory regimen for older AML patients, including patients with unfavorable-risk features [56] .
Liposomal formulation of cytarabine-daunorubicin
CPX-351, a liposomal formulation of a synergistic 5:1 molar ratio of cytarabine and daunorubicin, was studied in a randomized phase 2 trial in older AML patients and showed improved CR rate and survival for CPX-351 compared with '7 + 3' chemotherapy [57] . The liposomal formulation provides locally concentrated drug delivery and avoids some of the toxicities associated with these agents in conventional formulations. There was a trend to lower mortality with CPX-351. A phase 3 trial in older patients with high-risk AML comparing CPX-351 with conventional treatment is ongoing (NCT01696084).
Vosaroxin
Vosaroxin, a quinolone-derived DNA topoisomerase II inhibitor, has a similar mechanism of action to anthracyclines [58] . It induces site-specific DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to G2 arrest and apoptosis. However, unlike the anthracyclines, it is unaffected by Pglycoprotein over-expression or TP53 mutations. Vosaroxin may be particularly useful in elderly patients with AML [59] . In combination with decitabine, vosaroxin has shown an overall response of 88% in patients aged 60 to 70 years [60] . In relapsed/refractory patients, its combination with cytarabine has showed improved CR rates and OS as compared to cytarabine in monotherapy [61•] .
Inhibitors of isocitrate dehydrogenase
Specific point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) occur in AML and are associated with widespread changes in DNA methylation levels. The prevalence of missense mutations is between 5 and 20%. The frequency of IDH mutations strongly associates with intermediate-risk cytogenetics, NPM1 genotypes, and myeloproliferative neoplasm-derived AML. When mutated, IDH creates a molecule that alters the cell genetic programming. The IDH1 inhibitor, AG-120, and the IDH2 inhibitor, AG-221, are currently in phase 1 trials for relapsed AML, and the IDH1/2 inhibitor, AG-881, is in preclinical development (NCT02381886, NCT01915498, NCT02074839). Interim results of a phase 1/2 study with AG-221 demonstrated a response rate of 41% in patients with relapsed/refractory AML. Forty-four percent of patients showed a stable disease with for some of them transfusion independence [62] . Early results of AG-120 in patients with relapsed AML have shown similar evidence of efficacy. Response rate was 31% with 15% CR.
Histone deacetylase inhibitors
Vorinostat is a histone deacetylase inhibitor that has been shown to promote cell cycle arrest, apoptosis and differentiation of AML cells [63] . In combination with gemtuzumab ozogamicin (GO) a 46% response rate has been reported in older patients with normal or favorable cytogenetics [64] . A trial of vorinostat in combination with azacitidine is currently ongoing (NCT00946647). Available data for this combination demonstrated a response rate of 30 and 80% of patients survived at least 2 months [65] . Pracinostat is another histone deacetylase inhibitor, which showed promising results as a single agent in AML, and in combination with azacitidine in high-risk myelodysplastic syndromes [66] and AML (NCT01912274).
Bromodomain inhibitors
Bromodomains (BRDs) have been shown to have a role in AML. BRDs and the extra-C terminal domain (BET) proteins are involved in regulation of gene expression by binding to acetylated histones. The BRD4 gene is a promising therapeutic target [67] . There are multiple inhibitors of BRD4 in development, including JQ1 and I-BET151, and the BRD2/3/4 inhibitor, OTX015 [68] .
FMS-like tyrosine kinase 3 inhibitors
Internal tandem duplication (ITD) of the FLT3 gene leads to constitutively activated receptor tyrosine kinase (RTK) and its downstream signaling pathways, which in turn leads to dysregulation of cellular proliferation and enhanced cell survival. This activation of signaling pathways is important in the pathogenesis of AML. Inhibition of the RTKs using small molecules represents an attractive therapeutic target. Several molecules with activity against FLT3 have been tested. These first-generation FLT3 inhibitors (midostaurin, lestaurtinib, sunitinib, and sorafenib) showed only limited activity as single agents, but showed interesting results in combination with intensive chemotherapy.
Sorafenib is a multikinase inhibitor with activity against FLT3 and several receptor tyrosine kinases. In a phase 1 clinical trial, a clinical response was observed in 56% of cases [69] . Addition of sorafenib to chemotherapy improved disease-free survival (DFS) and OS in older patients with FLT3 mutation [70] . The median DFS and OS were 12.5 and 15 months, respectively, in patients with FLT3-ITD mutation, and 9 and 16.2 months in patients with FLT3-TKD mutation. The 30-day induction mortality was 9%, and there were no treatmentrelated deaths during the phases of consolidation and maintenance. In combination with hypomethylating agents (azacitidine), sorafenib has also shown promising efficacy. The overall response rate was 46% [71] and the median OS for responders was 7.8 months.
Addition of midostaurin to chemotherapy also showed improvements in terms of survival in younger adults, as compared to chemotherapy alone [72] . A phase 2b trial, showing a ≥50% reduction of bone marrow and peripheral blasts in 71% of patients, suggests further investigation of midostaurin in combination with other agents. Phase 2 trials studying the efficacy of midostaurin in combination with azacitidine (NCT01093573) or decitabine (NCT01846624) in older patients are currently ongoing.
The second-generation FLT3 inhibitor, quizartinib, is both a highly selective and potent inhibitor of FLT3. In a phase 1 study, responses were seen in 30% of all patients and 50% of FLT3-ITD-positive patients [73] . Results of a phase 2 study in relapsed/refractory FLT3-positive AML patients demonstrated a CR rate of 51% with a median OS of 25 weeks. These CR rates were confirmed in all phase 2 studies using quizartinib as a single agent [74, 75] . However, 50% of patients relapse within 3 months. The mechanism of resistance is the development of acquired mutations in the tyrosine kinase domain of the gene. A current phase 1/2 trial with quizartinib in combination with 5-azacitidine or low-dose cytarabine is ongoing in patients 960 years of age with previously untreated AML (NCT01892371).
Crenolanib represents a next-generation receptor tyrosine kinase that has activity against both FLT3-ITD and FLT3-D835 point mutants.
Crenolanib was demonstrated to have activity against mutations in the activation loop of FLT3 [76] . Crenolanib induced a CR with incomplete blood count recovery in 23% of patients (including older adults; median age 61 years), but in only 5% of patients who had received prior FLT3 inhibitors [77] . Crenolanib is currently being investigated in combination with intensive chemotherapy (NCT02283177).
Gilteritinib is a potent inhibitor of both FLT3-ITD and FLT3-TKD mutations. In the FLT3 mutant adult patient population (median age 61 years), the overall response rate was 57%. In adult AML, a phase 1 study in combination with intensive chemotherapy is ongoing (NCT02236013), as well as a phase 3 study randomizing gilteritinib versus savage chemotherapy (NCT02421939). A differentiation response to gilteritinib has recently been demonstrated among relapsed/refractory FLT3-mutated patients with NPM1 and DNMT3A mutations [78] .
Pacritinib is a third-generation TKI with activity against a number of targets of relevance to AML. The first clinical experience of pacritinib in AML demonstrated encouraging data in terms of tolerability and, in the challenging setting of relapsed/refractory FLT3-mutated AML, clinical response in one third of evaluable patients including patients of more than 60 years [79] .
Aurora kinase inhibitors
Aurora kinases play multiple roles in mitosis. Aurora kinase inhibitors bind to the kinase ATP binding site in a manner similar to that of the small-molecule kinase inhibitors. Most agents also inhibit kinases other than aurora kinases including ABL, JAK2, and FLT3 to varying degrees. Barasertib is an inhibitor of aurora B kinase. Single-agent barasertib has been investigated in a phase 2 study in older AML patients [80] . Treatment resulted in improved CR rate compared with low-dose cytarabine (35 versus 12%), but the difference was not significant in terms of OS. Toxicity profile was acceptable. The 30-day mortality rates were similar among treatment group. Furthermore, the response to barasertib was evident across all cytogenetic risk groups. The first trial of barasertib in combination with low-dose cytarabine demonstrated acceptable tolerability [81] . The response rate was 45%. A phase 2/3 is ongoing (NCT00952588).
Polo-kinase inhibitors
Polo-kinases are expressed during mitosis and regulate several key steps of cell division, including mitotic spindle assembly. A number of polo-like kinase inhibitors, including volasertib and rigosertib, are in phase 1/2 development for the treatment of AML. Volasertib is a selective and potent cell cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting polo-like kinase 1. A phase 2 study of volasertib in combination with low-dose cytarabine in previously untreated older patients found a response of 31%, compared with 13% with low-dose cytarabine alone. Responses were seen across cytogenetic groups. Median event-free survival and OS were significantly improved with the combination arm. More grade 3 adverse events were reported in the combination arm, but there was no difference in the 30-and 60-day mortality [82] . A phase 3 study, evaluating the efficacy, safety, and pharmacokinetics of volasertib plus low-dose cytarabine versus placebo plus low-dose cytarabine in newly diagnosed AML patients aged ≥65 years, has recently been completed with results pending (NCT01721876).
Mitochondrial inhibitors
In order to avoid apoptosis, a cell must express sufficient amounts of antiapoptotic proteins to bind and inactivate their pro-apoptotic counterparts. Failure to induce apoptosis can underlie lack of response to chemotherapy. The B cell lymphoma-2 (Bcl-2) family of proteins plays a vital role in regulating the intrinsic apoptotic pathway leading to programmed cell death via caspase activation. Elevated levels of anti-apoptotic Bcl-2 proteins in malignant cells prevent pore formation in the mitochondrial membrane by pro-apoptotic members of the Bcl-2 family, resulting in cell survival. Research efforts to develop small-molecule inhibitors of the Bcl-2 family proteins are ongoing [83] . A phase 2 trial has demonstrated that single-agent venetoclax (ABT-199) has clinical activity in relapse/refractory AML patients [84] . Caseinolytic protease P is a mitochondrial enzyme complex, which plays important roles in maintaining the integrity of mitochondrial respiration. Antagonizing the caseinolytic protease P pathway represents a promising drugable pathway in AML treatment [85] . Treatment with venetoclax plus decitabine or azacitidine showed a high response rate (76%) in newly diagnosed AML patients aged 65 years and over including those with adverse biologic disease features [86] . An overall response rate of 44% was demonstrated in a phase 1 study testing venetoclax plus low-dose cytarabine in previously untreated AML patients ≥65 years [87] .
DOT1L inhibitors
Histone methylation is responsible for altering gene-expression profiles. Smallmolecule inhibitors of DOT1L, a histone methyltransferase with aberrant activity, can disrupt leukemia progression in MLL-rearranged AML [88, 89] and DNMT3A-mutant AML [90] . A phase 1 trial testing DOT1L inhibitors in relapsed/refractory acute leukemia including elderly AML is currently ongoing (NCT01684150) [91] .
Monoclonal antibodies
The most experience with any antibody-based therapeutic has been with gemtuzumab ozogamicin (GO). GO is a humanized anti-CD33 monoclonal antibody (MoAb) conjugated to calicheamicin, a potent DNA-binding cytotoxic antibiotic. GO facilitates internalization of calicheamicin that causes DNA strand breaks leading to cell death [92] . In the ALFA-0701 study, fractionated doses of gemtuzumab ozogamicin in combination with daunorubicin and cytarabine significantly improved event-free survival and relapse-free survival in adult AML patients over 55 years old at 3 years compared with chemotherapy alone [93] . As patients not eligible for intensive chemotherapy, GO in monotherapy has shown a 23% of response rate [94] . The early mortality was 12%. Severe myelosuppression was observed with the recommended single-agent dose of GO. Hepatotoxicity (including hepatic veno-occlusive disease) has been reported in association with the use of GO as a single agent, especially in patients with underlying hepatic disease or abnormal liver function. In one randomized study comparing induction chemotherapy alone versus induction chemotherapy plus GO, there was no difference in response rates, early mortality, or toxicity, but there was a decreased relapse rate at 3 years and an improved survival in patients who received GO [95] . Improved outcomes have also been reported in patients receiving low-dose gemtuzumab ozogamicin combined with low-dose cytarabine compared with low-dose cytarabine alone (30% of responses versus 17%) [96] . However, this did not translate into a difference in terms of OS. There was no difference in terms of early mortality, but liver toxicity was significantly increased in the arm with GO. Combination with decitabine did not translate into improved survival when compared with historical data [97] . In combination with azacitidine, GO produced a 44% CR rate with a median OS of 11 months in patients aged 60-69 years, and 35% CR rate with again a median OS of 11 months in patients aged ≥70 years [98] . A phase 3 trial testing GO in monotherapy versus best supportive care is currently ongoing (NCT00091234). As post-remission therapy, GO did not shown any advantages in terms of relapse rates, DFS, or OS, in a phase 3 randomized study comparing three cycles of GO versus no post-remission-therapy [99] .
Advances in conjugation and linker technologies have resulted in SGN-CD33A (lintuzumab), a humanized CD33 MoAb with engineered cysteines carrying a synthetic DNA crosslinking pyrrolobenzodiazepine dimer via a protease-cleavable linker. SGN-CD33A is more potent than gemtuzumab ozogamicin in pre-clinical studies. An anti-leukemic activity was confirmed in a phase 1 study in older adults with 29% of responses [100•], but randomized studies did not show a survival benefit when it was added to other agents [101] . Therapeutic MoAbs elicit responses through direct killing or via antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis mechanisms. BI 836858 is a fully human anti-CD33 antibody, which is Fc engineered for increased binding to FCγRIIIa. It binds with low nanomolar affinity to human CD33 and displays decelerated internalization kinetics compared with previously developed CD33 monoclonal antibodies, thus making it suitable for exploitation of NK-mediated ADCC. In vitro, treatment of AML blasts with decitabine or 5-azacytidine did not compromise BI 836858-induced NK-cell-mediated ADCC [102] . Lintuzumab and 5-azacytidine also act in concert to promote tumor cell killing [103] . These data provide a rational for combination therapy of anti-CD33 MoAbs with hypomethylating agents in elderly patients with AML. Initial results from an ongoing phase 2 study combining SGN-CD33A with azacitidine or decitabine are promising with a response rate of 65% and 8-week mortality of 4%, and with 85% of treated patients having a ≥50% reduction in blasts [104] .
Future directions
Compared with the younger adult population, the older population with AML is a heterogeneous cohort in terms of physical performance, physiological and psycho-cognitive functions, and socio-economic environment. After 70 years old, chronological age does not adequately guide to the optimal therapeutic approach. A commonly accepted definition of unfitness to intensive and nonintensive chemotherapy is therefore warranted. The management of these patients deserves a multi-step procedure aiming to the assessment of the patient's physiological age. In this setting, treatment decision-making should be influenced not only by the characteristics of AML but also by geriatric assessment. Geriatric assessment will not only help to identify patients with a higher risk of morbidity/mortality, but will also allow for a better management of their vulnerabilities. Treatment recommendations for elderly patients with AML need therefore certainly to be individualized.
While two decades ago, supportive care was the only option for about 60% of elderly patients with AML, the development of lower-intensity treatment due to the discovery of novel agents has granted to a significant proportion of these patients, not eligible for intensive treatment, to access to a disease-specific therapy. Activating mutations in signaling pathways have been described in approximately 60% of AML patients. Combination of drugs with different mechanisms of action might offer a potential benefit to elderly patients. The main intention is to synergize the positive effects of each drug on the defective hematopoiesis while sparing potential side effects and toxicities. An important goal would be to identify reliable biomarkers able to predict which patients are more likely to achieve clinical response. It is therefore time for changing the treatment of elderly AML. We should reappraise thinking of a comprehensive and individualized approach with the aim to find an accurate balance between efficacy of therapy and acceptable quality of life. After referring first to the geriatric evaluation, the performance status and the presence of potential comorbidities for selecting patients who might be considered "fit" or "unfit" for intensive chemotherapy, and those who might receive only supportive care, physician's therapeutic decision-making should take into account cytogenetics and molecular markers (when available) in order to use specific targeted therapies, but also the proliferative and/or invasive AML characteristics, a rapid cell cycle turnover being theoretically not recommended to drugs for which a delayed efficacy is expected.
Summary
AML is primarily a disease of older adults. The optimal treatment for older adults remains largely undefined. Although criteria that define fitness for intensive chemotherapy remain to be standardized, intensive induction chemotherapy is rarely beneficial for frail older adults and those with poor-risk disease. Hence, novel treatment strategies are warranted. Treatment options for the majority of older AML patients are limited to low-intensity strategies that aim to reduce treatment-related mortality and provide disease control. The purpose of this review was to highlight the currently available promising investigational approaches for treating older AML patients who are ineligible for intensive chemotherapy.
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